Antithrombotic activity of TNF-α

Journal of Clinical Investigation

Volumn 112, Issue 10, 2003, Pages 1589-1596

  Cambien, Beatrice ^a,b   Bergmeier, Wolfgang ^a,b   Saffaripour, Simin ^a   Mitchell, Heather A ^a   Wagner, Denisa D ^a,b  

^a CENTER FOR BLOOD RESEARCH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; N(G) METHYLARGININE; NITROUS OXIDE; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERY INJURY; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS;

EID: 0347988038     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI19284     Document Type: Article

References (42)

1. Vallet, B., and Wiel, E. 2001. Endothelial cell dysfunction and coagulation. Crit. Care Med 29(Suppl.):S36-S41.
2. Ruberg, F.L., Leopold, J.A., and Loscalzo, J. 2002. Atherothrombosis: plaque instability and thrombogenesis. Prog. Cardiovasc. Dis. 44:381-394.
3. Lip, G.Y., Chin, B.S., and Blann, A.D. 2002. Cancer and the prothrombotic state. Lancet Oncol. 3:27-34.
4. Korte, W. 1997. Veno-occlusive disease of the liver after bone marrow transplantation: is hypercoagulability really part of the problem? Blood Coagul. Fibrinolysis. 8:367-381.
5. Esmon, C.T. 1999. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract. Res. Clin. Haematol. 12:343-359.
6. Esmon, C.T. 2000. Does inflammation contribute to thrombotic events? Haemostasis 30(Suppl.):34-40.
7. Philippe, C., et al. 1993. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am. J. Pathol. 143:1713-1723.
8. Tacchini-Cottier, F., Vesin, C., Redard, M., Buurman, W., and Piguet, P.F. 1998. Role of TNFR1 and TNFR2 in TNF-induced platelet consumption in mice. J. Immunol. 160:6182-6186.
9. Andre, P., et al. 2002. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat. Med 8:247-252.
10. Bergmeier, W., Rackebrandt, K., Schroder, W., Zirngibl, H., and Nieswandt, B. 2000. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood. 95:886-893.
11. Morton, L.F., Hargreaves, P.G., Farndale, R.W., Young, R.D., and Barnes, M.J. 1995. Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. Biochem. J. 306:337-344.
12. Peschon, J.J., et al. 1998. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160:943-952.
13. Laubach, V.E., Shesely, E.G., Smithies, O., and Sherman, P.A. 1995. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. U. S. A. 92:10688-10692.
14. Denis, C., et al. 1998. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc. Natl. Acad. Sci. U. S. A. 95:9524-9529.
15. Ni, H., et al. 2000. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J. Clin. Invest. 106:385-392.
16. Subramaniam, M., et al. 1996. Defects in hemostasis in P-selectin-deficient mice. Blood. 87:1238-1242.
17. Andre, P., Hartwell, D., Hrachovinova, I., Saffaripour, S., and Wagner, D.D. 2000. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc. Natl. Acad. Sci. U. S. A. 97:13835-13840.
18. Mohler, K.M., et al. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1548-1561.
19. Combes, V., et al. 1999. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J. Clin. Invest. 104:93-102.
20. Satta, N., et al. 1994. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J. Immunol. 153:3245-3255.
21. Giesen, P.L., et al. 1999. Blood-borne tissue factor: another view of thrombosis. Proc. Natl. Acad. Sci. U. S. A. 96:2311-2315.
22. Loscalzo, J. 2001. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 88:756-762.
23. Billiau, A., and Vandekerckhove, F. 1991. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur. J. Clin. Invest. 21:559-573.
24. Wakefield, T.W., et al. 1991. Deep venous thrombosis in the baboon: an experimental model. J. Vasc. Surg. 14:588-598.
25. Zhao, L., et al. 2002. LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood. 100:3233-3239.
26. Piguet, P.F., Vesin, C., and Da Kan, C. 2002. Activation of platelet caspases by TNF and its consequences for kinetics. Cytokine. 18:222-230.
27. Papapetropoulos, A., Rudic, R.D., and Sessa, W.C. 1999. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc. Res. 43:509-520.
28. Olsen, S.B., et al. 1996. Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model. Circulation. 93:327-332.
29. Yan, Z.Q., Yokota, T., Zhang, W., and Hansson, G.K. 1996. Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circ. Res. 79:38-44.
30. MacNaul, K.L., and Hutchinson, N.I. 1993. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem. Biophys. Res. Commun. 196:1330-1334.
31. Liu, S.F., Barnes, P.J., and Evans, T.W. 1997. Time course and cellular localization of lipopolysaccharide-induced inducible nitric oxide synthase messenger RNA expression in the rat in vivo. Crit. Care Med. 25:512-518.
32. Gosgnach, W., Messika-Zeitoun, D., Gonzalez, W., Philipe, M., and Michel, J.B. 2000. Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am. J. Physiol. Cell Physiol. 279:C1880-C1888.
33. Chyu, K.Y., et al. 1999. Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. Circ. Res. 85:1192-1198.
34. Raza, A. 2000. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. 50:229-235.
35. Sicotte, N.L., and Voskuhl, R.R. 2001. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 57:1885-1888.
36. Sandborn, W.J., and Hanauer, S.B. 1999. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 5:119-133.
37. Lejeune, F.J., Ruegg, C., and Lienard, D. 1998. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 10:573-580.
38. Matsushita, K., et al. 2003. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide sensitive factor. Cell. 115:1-20.
39. Andre, P., et al. 2000. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 96:3322-3328.
40. Nathan, C. 2002. Points of control in inflammation. Nature. 420:846-852.
41. Yeo, E.L., Sheppard, J.A., and Feuerstein, I.A. 1994. Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model). Blood. 83:2498-2507.
42. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature. 420:885-891.